Hepatocellular Carcinoma
Conditions
Keywords
HCC, Unresectable, BioPearl®, TACE, Chemoembolization
Brief summary
The primary objective of the study is to confirm safety and efficacy of BioPearl™ microspheres loaded with doxorubicin in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
Detailed description
This is a prospective, single arm, multi-centre, post-market study to further assess safety and efficacy in 20 unresectable HCC patients treated with Doxorubicin loaded BioPearl™ microspheres. After the treatment procedure, all patients will undergo clinical follow-up until disease progression and/or next treatment option after which patients will be followed for survival. Patients will be followed up to a maximum of 3 years.
Interventions
DEVICEChemoembolization
First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach. Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved.
Sponsors
Terumo Europe N.V.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is at least 18 years old. 2. Patient with HCC confirmed by histology or according to the latest applicable version of the EASL criteria. 3. Patient with a single nodular tumor 6 cm or less in longest diameter or patient with no more than three tumor nodules, each 4 cm or less in longest diameter. Infiltrative disease is excluded. 4. BCLC B patient or BCLC A patient not a candidate for curative treatment at the time of study inclusion or who has failed/recurred after resection/ablation. 5. Patient deemed treatable in one session for initial treatment. 6. Normal liver or compensated cirrhosis with preserved liver function (Child-Pugh Class A). 7. Total bilirubin ≤ 2.0 mg/dl. 8. Patient with no ascites or with medically controlled ascites. 9. Adequate renal function (serum creatinine \< 1.5 X ULN). 10. Patient has provided written informed consent.
Exclusion criteria
1. Patient previously treated with any systemic therapy for HCC. 2. Patient previously treated with a loco-regional therapy for HCC. Prior resection/ablation is allowed as per inclusion criteria 4. 3. Eligible for curative treatment at the time of study inclusion. 4. Advanced liver disease: Child-Pugh's B-C class or active gastrointestinal bleeding, encephalopathy. 5. Advanced tumoral disease: BCLC class C or D (vascular invasion - even segmental, extra-hepatic spread or cancer-related symptoms performance status ≥1). 6. Patient with another primary tumor. 7. Patient with history of biliary tree disease or biliary dilatation. 8. Portal vein thrombosis, porto-systemic shunt, hepatofugal blood flow or absent portal blood flow in the liver area to be treated. 9. Contraindication to multiphasic CT and MRI (e.g. allergy to contrast media). 10. Any other contraindication for embolization procedure or doxorubicin treatment. 11. Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials. 12. In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study. 13. Pregnant or breast-feeding women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of grade 3-4-5 adverse events related with procedure or study device | 4 weeks | Safety by monitoring and evaluating all grade 3-4-5 adverse events related with procedure or study device |
| Tumor response | 4 weeks | Tumor response rate assessed by mRECIST criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to un-TACEable progression | 3 years | Time from treatment to un-TACEable progression of the treated lesion according to EASL criteria |
| Hepatic progression free survival | 3 years | Time from treatment to progression anywhere in the liver according to mRECIST criteria or death from any cause |
| Technical success | 1 day | Ability to reach stasis in the treated tumor feeding arteries during chemoembolization procedure |
| Overall survival | 3 years | Time from treatment until death from any cause |
| Best overall response | 3 years | Best response of treated tumor(s) recorded during the course of the study according to mRECIST criteria |
| Progression free survival | 3 years | Time from treatment to progression in the liver or outside the liver or death from any cause |
| Time to progression of treated tumor(s) | 3 years | Time from treatment to progression of the treated lesion according to mRECIST criteria |
Countries
Belgium
Outcome results
None listed